Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16371883 | 0.98 | CA12 (0.53) | CA12CA2CA9CA1ALDH1A1 | |
| SCHEMBL11051 | 0.98 | CA12 (0.53) | CA12CA2CA9CA1ALDH1A1 | |
| SCHEMBL28296540 | 0.95 | CA12 (0.52) | CA12CA2CA9CA1ALDH1A1 | |
| Iodide SCHEMBL11631405 | 0.95 | CA12 (0.52) | CA12CA2CA9CA1ALDH1A1 | |
| SCHEMBL10385905 | 0.95 | CA12 (0.52) | CA12CA2CA9CA1ALDH1A1 | |
| Water SCHEMBL10657216 | 0.95 | CA12 (0.52) | CA12CA2CA9CA1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL728400 | 0.95 | CA12 (0.52) | CA12CA2CA9CA1ALDH1A1 | |
| Cyanide SCHEMBL29655773 | 0.91 | CA12 (0.48) | CA12CA2CA9CA1ALDH1A1 | |
| SCHEMBL821094 | 0.89 | ALDH1A1 (0.54) | CA12CA2CA9CA1ALDH1A1 | |
| SCHEMBL27549272 | 0.87 | CA12 (0.46) | CA12CA2CA9CA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021262825-A2 | DISRUPTING LIPID SYNTHESIS: A NOVEL TARGET FOR BROAD-SPECTRUM HOST-DIRECTED ANTI-VIRULENCE THERAPEUTICS | GENETIC NETWORKS, LLC (US) | 2021-12-30 | — | — | WO | claimed |
| US-10639308-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-05-05 | — | — | US | claimed |
| US-20200087367-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | ACCELERON PHARMA INC. | 2020-03-19 | — | — | US | claimed |
| CN-110603049-A | Compositions and methods for treating heart failure | 阿塞勒隆制药公司 | 2019-12-20 | — | — | CN | claimed |
| EP-2953558-B1 | EMBRYO TRANSFER CATHETER | SILLENDER MARK (AU) | 2019-08-28 | — | — | EP | claimed |
| US-10154856-B2 | Therapeutic substance transfer catheter and method | SILLENDER MARK (AU) | 2018-12-18 | — | — | US | claimed |
| WO-2018144968-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | ACCELERON PHARMA INC. (US) | 2018-08-09 | — | — | WO | claimed |
| EP-3160464-A1 | USE OF BUSPIRONE METABOLITES | Contera Pharma APS (DK) | 2017-05-03 | — | — | EP | claimed |
| WO-2015197079-A1 | USE OF BUSPIRONE METABOLITES | CONTERA PHARMA APS (DK) | 2015-12-30 | — | — | WO | claimed |
| US-20150359566-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | SILLENDER MARK (US) | 2015-12-17 | — | — | US | claimed |
| EP-2953678-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | Sillender, Mark (AU) | 2015-12-16 | — | — | EP | claimed |
| EP-2953558-A1 | EMBRYO TRANSFER CATHETER AND METHOD | Sillender, Mark (AU) | 2015-12-16 | — | — | EP | claimed |
| US-20150342642-A1 | EMBRYO TRANSFER CATHETER AND METHOD | SILLENDER MARK (US) | 2015-12-03 | — | — | US | claimed |
| WO-2015051336-A1 | COMPOSITIONS AND METHODS FOR TREATING PELVIC PAIN AND OTHER CONDITIONS | WISE DAVID (US) | 2015-04-09 | — | — | WO | claimed |
| WO-2014121332-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | SILLENDER MARK (AU) | 2014-08-14 | — | — | WO | claimed |
| WO-2014121333-A1 | EMBRYO TRANSFER CATHETER AND METHOD | SILLENDER MARK (AU) | 2014-08-14 | — | — | WO | claimed |
| US-20100034884-A1 | LUMINESCENT CONDUCTING NANO-DRUG CRYSTAL ULTRA-THIN FILM SELF-ASSEMBLY AND USES | ZHONGSHAN HOSPITAL, FUDAN UNIVERSITY (CN) | 2010-02-11 | — | — | US | claimed |
| US-7125559-B2 | Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one myorelaxing agent | L'OREAL (FR) | 2006-10-24 | — | — | US | claimed |
| US-20240228520-A9 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-1992000729-A1 | DOSAGE FORM FOR ADMINISTERING A DRUG TO EFFECT CIRCADIAN THERAPY | ALZA CORPORATION (US) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087367-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | BMPR2, BMPR1B, BMP1 | CA12 722/4885CA2 1434/4885CA9 424/4885 |
| US-10639308-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | CA12 4513/4885CA2 1774/4885CA9 3467/4885 |
| US-20240228520-A9 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | P2RY1, P2RY11, GMPS | CA12 4220/4885CA2 1642/4885CA9 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.